506-30-9 Purity
99%+
If you have any other questions or need other size, please get a quote.
Specification
In a prospective randomized clinical trial, Diphenylcyclopropenone (DPCP), a well-established topical immunotherapeutic agent, was investigated for its efficacy in treating moderate to severe alopecia areata (AA), both as a monotherapy and in combination with anthralin. A total of 50 patients were randomly assigned into two groups: Group D received DPCP alone, while Group D/A was treated with DPCP in conjunction with topical anthralin. Treatment spanned a duration of six months, with the primary endpoint being the percentage of hair regrowth, and secondary outcomes including the frequency and severity of treatment-related adverse effects.
DPCP was applied weekly to sensitized scalp areas following a standard escalation protocol. In the combination group, anthralin was applied daily for 30-60 minutes before being washed off. Clinical response was assessed using standardized photographic evaluations and regrowth percentage scales. After 6 months, both groups showed comparable efficacy: complete hair regrowth occurred in 18.75% of Group D and 15.79% of Group D/A. Notably, >50% regrowth was observed in 47% of patients in the DPCP/anthralin group versus 31% in the DPCP-only group. However, these differences did not reach statistical significance (P = 0.696).
The study concluded that anthralin did not provide a synergistic benefit when combined with DPCP. Nevertheless, this research highlights the continued relevance of DPCP as a cornerstone in topical immunotherapy for alopecia areata.
Diphenylcyclopropenone (DPCP) has been demonstrated as a versatile reagent for site-selective bioconjugation, engaging in a unique reaction with 1,2-aminothiols in aqueous buffer (pH 7.4) to form amide linkages while releasing free thiol groups. This transformation, which proceeds under mild physiological conditions, enables modular and orthogonal protein labeling strategies. In the reported method, an N-terminal cysteine-containing peptide was treated with DPCP-Cl, a chlorinated analog of DPCP, to install the reactive DPCP moiety. Subsequent in situ thiol-maleimide coupling and tyrosine-diazonium labeling were performed sequentially in a single reaction vessel. This one-pot, triple-labelling strategy underscores the utility of DPCP in constructing multifunctional bioconjugates. Structural tuning of DPCP substituents allowed modulation of the coupling kinetics, with a Hammett reaction constant of +3.68, indicating strong electronic sensitivity. The reaction's chemoselectivity and aqueous compatibility make DPCP an efficient platform for developing advanced protein modification tools in chemical biology and therapeutic conjugate design.
The molecular formula of Diphenylcyclopropenone is C15H10O.
The synonyms for Diphenylcyclopropenone are Diphencyprone and 2,3-Diphenylcycloprop-2-en-1-one.
The molecular weight of Diphenylcyclopropenone is 206.24 g/mol.
Diphenylcyclopropenone has a role as a photosensitizing agent, a hapten, and a drug allergen.
Diphenylcyclopropenone has been used in trials studying the treatment and basic science of Melanoma, Ultraviolet Rays, Immunosuppression, Neoplasm Metastasis, and Hypersensitivity, Delayed, among others.
The IUPAC name of Diphenylcyclopropenone is 2,3-diphenylcycloprop-2-en-1-one.
The InChI of Diphenylcyclopropenone is InChI=1S/C15H10O/c16-15-13(11-7-3-1-4-8-11)14(15)12-9-5-2-6-10-12/h1-10H.
The InChIKey of Diphenylcyclopropenone is HCIBTBXNLVOFER-UHFFFAOYSA-N.
The CAS number of Diphenylcyclopropenone is 886-38-4.
The ChEMBL ID of Diphenylcyclopropenone is CHEMBL1373467.